Clinical Trial News and Research

RSS

Childrens Hospital Los Angeles receives $1M NCI grant for eye port clinical trial to treat retinoblastoma in children

The Vision Center at Childrens Hospital Los Angeles has been awarded a $1 million grant from the National Cancer Institute (NCI) to conduct a clinical trial on a new drug delivery system to treat young children diagnosed with retinoblastoma. The device is designed to deliver chemotherapy through a tiny silicone cup sealed to the outer surface (sclera) of the eye, which can more directly target cancer cells and greatly reduce the side effects caused by current chemotherapy treatments.

14 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

Real-time data access can improve quality and efficiency of drug development

Technologies to capture and view clinical trial data in real time offer great potential to enhance patient safety, strengthen trial quality and accelerate drug development, but they also require new guidelines to ensure trial integrity, according to the white paper "Using Real-Time Data to Drive Better Decisions, Faster" released today by Quintiles, the world's leading biopharmaceutical services company.

14 Oct 2010

Patient-specific experimental vaccine to prevent recurrence of glioblastoma

Mary Lee's primary care physician is also a family friend. When he walked into the exam room in October 2006 with tears in his eyes, she knew something serious was wrong. But she was shocked to learn she had a brain tumor - and later found out it was the most aggressive malignant type, a glioblastoma multiforme.

14 Oct 2010

Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.

14 Oct 2010

Antidepressant Reboxetine ineffective: Review

According to a new study, an antidepressant prescribed over the last 13 years is ineffective and potentially harmful. The drug in question is called Reboxetine and is available under the name of Edronax. The study showed that it works no better than a placebo.

13 Oct 2010

MEDTOX Scientific third quarter total revenues increase 15.9% to $25.8 million

MEDTOX Scientific, Inc. today announced results for the third quarter ended September 30, 2010. MEDTOX achieved record revenues and gross profit in the quarter.

13 Oct 2010

Study examines restrictive strategy of RBC transfusion in patients undergoing elective cardiac surgery

Use of stricter guidelines for the use of red blood cell transfusions for patients undergoing cardiac surgery was associated similar rates of death and severe illness compared to patients who received more transfusions, according to a study in the October 13 issue of JAMA. Another study in this issue of JAMA examines the variation in the use of blood transfusions for patients undergoing cardiac surgery.

13 Oct 2010

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

A combination of Biothera's Imprime PGG and cetuximab (Erbitux) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients participating in a Phase Ib/IIa clinical trial. The completed trial results were released yesterday at the 35th European Society for Medical Oncology (ESMO) Congress.

13 Oct 2010

Lithera receives Notice of Allowance from USPTO for LIPO-102 patent application

Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

13 Oct 2010

Threshold announces TH-302 Phase 1/2 clinical trial interim results

Threshold Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1/2 clinical trial in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented at the European Society for Medical Oncology (ESMO) Annual Meeting being held in Milan, Italy.

13 Oct 2010

JAMA publishes Probuphine Phase 3 clinical trial data

Titan Pharmaceuticals, Inc. today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA).

13 Oct 2010

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Kennedy Krieger Institute announced today the launch of a first‐of‐its‐kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DMD).

13 Oct 2010

New cancer initiative may promote rapid drug development

Greenville Hospital System University Medical Center (GHS) unveiled details of its new Institute for Translational Oncology Research, a visionary cancer initiative that will help pave the way for new breakthroughs in rapid drug development, diagnostic discovery and advanced cancer care. ITOR is part of the GHS Cancer Center, a recognized regional multi-disciplinary center.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

Retina Implant announces opening of new manufacturing plant in Tübingen-Reutlingen

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the opening of a new manufacturing plant to meet anticipated demand for their implants. The company's second human clinical trial will be expanding outside of Germany in early 2011 to European countries including the U.K. and Italy and discussions are underway for potential clinical trials in the United States and Asia. Also looking ahead, the new facility meets manufacturing capabilities required for CE mark approval.

13 Oct 2010

US Oncology enrolls 1,000th patient in Phase I clinical trial

US Oncology, Inc., the nation's leading integrated oncology company, announced today that it has enrolled the 1,000th patient in a Phase I clinical trial through its US Oncology Research Network. Phase I clinical trials present special challenges, including increased safety concerns, higher variability of patient disease, more complex trial designs, and some first-in-human trials, making Phase I trials more difficult to operate in the community setting.

13 Oct 2010

HSV1716 clinical trial for childhood cancer receives FDA grant

A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S. Food and Drug Administration grant to support the research.

13 Oct 2010

Incept completes first U.S. human clinical trial of SMART Start Embryo Culture System

Incept BioSystems, Inc. a privately-held biomedical device company using patented, microfluidic technology developed at the University of Michigan, announced today the completion of the first U.S. human clinical trial of its proprietary, SMART Start Embryo Culture System, and the recent submission of a 510(k) application to the U.S. Food & Drug Administration.

13 Oct 2010

USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth

Columbia Laboratories, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Watson Pharmaceuticals, Inc. a Notice of Allowance for a key patent for the use of progesterone to treat or prevent preterm birth. The USPTO issues a Notice of Allowance to report that a patent application has been examined and is allowed for issuance as a patent. The patent is expected to issue within three months upon payment of required fees.

12 Oct 2010

Clinical Trial News and Research

Childrens Hospital Los Angeles receives $1M NCI grant for eye port clinical trial to treat retinoblastoma in children

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Real-time data access can improve quality and efficiency of drug development

Patient-specific experimental vaccine to prevent recurrence of glioblastoma

Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer

Antidepressant Reboxetine ineffective: Review

MEDTOX Scientific third quarter total revenues increase 15.9% to $25.8 million

Study examines restrictive strategy of RBC transfusion in patients undergoing elective cardiac surgery

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

Lithera receives Notice of Allowance from USPTO for LIPO-102 patent application

Threshold announces TH-302 Phase 1/2 clinical trial interim results

JAMA publishes Probuphine Phase 3 clinical trial data

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

New cancer initiative may promote rapid drug development

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

Retina Implant announces opening of new manufacturing plant in Tübingen-Reutlingen

US Oncology enrolls 1,000th patient in Phase I clinical trial

HSV1716 clinical trial for childhood cancer receives FDA grant

Incept completes first U.S. human clinical trial of SMART Start Embryo Culture System

USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News